<DOC>
	<DOCNO>NCT02739048</DOCNO>
	<brief_summary>1 . The overall objective study : By evaluate curative effect CSAP localize prostate cancer , locally advanced prostate cancer metastasis advance prostate cancer , change state cellular immunity humoral immunity CSAP . Validate clinical therapeutic effect kind prostate cancer , well change immune status CSAP . 2 . The main content study : 1 . Included samples patient hospital CSAP . The sample capacity plan 80 . The main purpose study observe overall survival rate , disease free survival rate , progress time PSA biochemical recurrence well disease progress time . 2 . Measure change concentration peripheral blood T lymphocyte subset ( CD3 + T , CD4 + T , CD8 + T , CD4 + / CD8 + T , NK cell ) regulatory T cell cryoablation within 1 month , 3 month 6 month . 3 . Measure change concentration peripheral blood IFN-1 , IL-4 , IFN-1/IL-4 ratio ( Thl/Th2 ratio ) , detect secretion CD4 + Th tumor-specific IFN-l activity tumor-specific killer CD8 + CTL cryoablation within 2 week 1 month . 4 . Before cryoablation , detect expression distribution Follistatin-Like1 ( FSTL-1 ) , Besides , verify connection number activation ratio tumor local dendritic cell ( DC ) FSTL-1 , evaluate cryoablation effect immune response .</brief_summary>
	<brief_title>Changes Immunologic Function Patients Prostate Cancer Induced After Cryoablation .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>patient diagnosed prostate cancer pathology age patient 40 80 year old receive treatment like radical prostatectomy , radiotherapy , etc receive surgery bad performance status abnormal coagulation function receive treatment CSAP want achieve CSAP reason</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>